Skip to main content
$23.50 $0.68 (3.0%)

03:52 PM EDT on 05/25/22

VIR Biotechnology (NASDAQ:VIR)

CAPS Rating: 3 out of 5

Current Price $23.50 Mkt Cap $3.0B
Open $22.96 P/E Ratio 2.46
Prev. Close $22.82 Div. (Yield) $0.00 (0.0%)
Daily Range $22.96 - $23.89 Volume 502,637
52-Wk Range $18.21 - $58.00 Avg. Daily Vol. 1,920,269

Caps

How do you think NASDAQ:VIR will perform against the market?

Add Stock to CAPS Watchlist

All Players

22 Outperform
1 Underperform
 

All-Star Players

7 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VIR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (48.83)
Submitted January 27, 2020

Vir Biotech up 21% on coronavirus buying frenzyJan. 27, 2020 10:19 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor Thinly traded Vir Biotechnology (VIR +20.9%) is up up on almost a 4x surge in volume, albeit a… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:VIR VS S&P 500 (SPY)

NASDAQ:VIR Summary

Fools bullish on NASDAQ:VIR are also bullish on:

Fools bearish on NASDAQ:VIR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VIR.

Recs

0
Member Avatar TMFSaintCroix (98.39) Submitted: 2/19/2022 6:53:05 AM : Outperform Start Price: $14.10 NASDAQ:VIR Score: +37.37

In the short term I like Vir because the market is seriously undervaluing its COVID treatment.

https://www.fool.com/investing/2022/02/10/3-biotech-stocks-that-are-too-cheap-to-ignore/

It's possible that we'll develop "herd immunity" to COVID, and when we catch mutating strains in the future, we'll be asymptomatic. If so the future COVID revenues will probably dry up. But another possible future is that COVID continues to mutate, and continues to be a threat, for a long time. If that's the case, Vir is going to be a spectacular investment.

Regardless, the massive revenues for 2022 are a certainty. The drug has an EUA, and it's already been sold. And the FDA has withdrawn the EUA for its competitors, because they don't work on the Omicron mutation.

Glaxo is selling and manufacturing the drug, and Vir is taking almost 75% of the revenues from the sales. Vir will make billions this year, and at a $4 billion market cap, it's dramatically underpriced on that basis alone.

Vir is also the opposite of a one-hit wonder. It's got a whole platform full of interesting molecules, including one that might be an effective cure for hepatitis B. The risk/reward ratio for Vir is amazing right now. Bought shares this week.

Recs

0
Member Avatar TMFAdriaCimino (< 20) Submitted: 6/1/2021 6:48:19 AM : Outperform Start Price: $42.73 NASDAQ:VIR Score: -38.83

Vir should benefit from its first commercialized product, its antibody treatment for covid. It may stand out because so far the product works against all variants of concern.

Recs

1
Member Avatar Bigsef77 (48.83) Submitted: 1/27/2020 1:40:44 PM : Outperform Start Price: $13.08 NASDAQ:VIR Score: +52.29

Vir Biotech up 21% on coronavirus buying frenzy
Jan. 27, 2020 10:19 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor
Thinly traded Vir Biotechnology (VIR +20.9%) is up up on almost a 4x surge in volume, albeit a relatively modest 514K shares, as the animal spirits continue to sweep up companies that may be positioned to benefit from the coronavirus outbreak.

The company has four technology platforms that it is leveraging to develop treatments for infectious diseases, including influenza and tuberculosis.

Leaderboard

Find the members with the highest scoring picks in VIR.

Score Leader

slnoutperform

slnoutperform (41.93) Score: +261.68

The Score Leader is the player with the highest score across all their picks in VIR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Bigsef77 48.83 11/13/2019 6/28/2021 Outperform 5Y $13.08 +81.12% +28.83% +52.29 1 Comment
TheFall2021 94.90 1/21/2021 Underperform 5Y $43.03 -44.95% +3.53% +48.47 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. TMFSaintCroix 98.39 11/1/2019 Outperform 5Y $14.10 +68.01% +30.64% +37.37 1 Comment
Madmykl 96.70 3/3/2022 Outperform 5Y $24.81 -4.51% -9.56% +5.05 0 Comment
cruisin25 59.35 3/31/2022 Outperform 3M $26.11 -9.27% -13.01% +3.75 0 Comment
GoldMiner20 < 20 5/23/2022 Outperform 5Y $23.95 -1.09% +1.41% -2.49 0 Comment
TMFGBudwell < 20 1/10/2022 Outperform 5Y $33.80 -29.91% -13.91% -16.01 0 Comment
77lucky < 20 10/6/2021 Outperform 5Y $34.24 -30.81% -7.31% -23.50 0 Comment
Espi < 20 7/15/2021 Outperform 1Y $36.28 -34.70% -8.39% -26.32 0 Comment
MoSteele 43.94 12/4/2020 Outperform 3Y $31.49 -24.77% +7.73% -32.50 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VIR.